July 25th 2024
The study highlights the need for personalized treatments, suggesting that this combination therapy is most beneficial when tailored to individual risk profiles.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Emerging Agents Augment Melasma Modalities
April 9th 2021An array of agents for blocking visible light and lightening skin are joining the armamentarium to treat melasma. Despite this expanding number of therapeutic interventions, melasma is a chronic, therapeutically challenging disease for which there is no cure, so treatment plans should address both management of the disease and patient expectations.
Cysteamine cream, tranexamic acid mesotherapy reveal similar efficacy, different safety
October 14th 2020Cysteamine cream and tranexamic acid mesotherapy demonstrated similar efficacy but yielded different safety results when being compared as a treatment for melasma, according to a recently published study.
730 nm picosecond laser safe, effective for benign pigmented lesions
October 13th 2020Lasers typically used for tattoo removal are on the rise as a possible treatment for melasma, with the novel 730 nm picosecond laser (PicoWay, Candela) being the most recently studied device which showed to be safe and effective for treating benign pigmented lesions.
Sunscreen demonstrates strong therapeutic properties in patients with pigmentary disorders
September 2nd 2020The importance of blocking visible light in the treatment of pigmentary disorders is becoming clearer. One expert says photoprotection in patients with pigmentary conditions is a therapeutic cornerstone.
Characteristics that distinguish facial hyperpigmentation disorders
September 1st 2020Effective treatment first requires accurate diagnosis, one expert says. He offers tips to distinguish melasma from other disorders and suggests some patients may need to be checked for diabetes and metabolic syndrome if they exhibit certain presentations.
Facial pigmentation impacts quality of life regardless of clinical severity
August 7th 2020In a study of more than 200 men and women, clinicians scored patients’ pigmentation taking into account how much of the face was impacted and compared scores to patients’ responses to the Skindex-16 questionnaire.
Investigational cream may be effective to deliver tranexamic acid
January 29th 2020Melasma responds well to oral and locally injected tranexamic acid treatments, but clinical results from topical tranexamic acid administration have been disappointing, researchers report. They examined efficacy of a co-enhancer as a method to deliver the treatment.
A closer look at tranexamic acid for melasma
November 12th 2019A growing body of evidence supports treating melasma with systemic or intradermal tranexamic acid. But melasma patients often relapse when they stop taking the antifibrinolytic agent, and research on tranexamic acid’s long-term efficacy and safety is limited.